Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England

There are concerns that sotrovimab has reduced efficacy at reducing hospitalisation risk against the BA.2 sub‐lineage of the Omicron SARS‐CoV‐2 variant. We performed a retrospective cohort (n = 8850) study of individuals treated with sotrovimab in the community, with the objective of assessing wheth...

Descripción completa

Detalles Bibliográficos
Autores principales: Harman, Katie, Nash, Sophie Grace, Webster, Harriet H., Groves, Natalie, Hardstaff, Jo, Bridgen, Jessica, Blomquist, Paula B., Hope, Russell, Ashano, Efejiro, Myers, Richard, Rokadiya, Sakib, Hopkins, Susan, Brown, Colin S., Chand, Meera, Dabrera, Gavin, Thelwall, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225304/
https://www.ncbi.nlm.nih.gov/pubmed/37246147
http://dx.doi.org/10.1111/irv.13150
_version_ 1785050372211998720
author Harman, Katie
Nash, Sophie Grace
Webster, Harriet H.
Groves, Natalie
Hardstaff, Jo
Bridgen, Jessica
Blomquist, Paula B.
Hope, Russell
Ashano, Efejiro
Myers, Richard
Rokadiya, Sakib
Hopkins, Susan
Brown, Colin S.
Chand, Meera
Dabrera, Gavin
Thelwall, Simon
author_facet Harman, Katie
Nash, Sophie Grace
Webster, Harriet H.
Groves, Natalie
Hardstaff, Jo
Bridgen, Jessica
Blomquist, Paula B.
Hope, Russell
Ashano, Efejiro
Myers, Richard
Rokadiya, Sakib
Hopkins, Susan
Brown, Colin S.
Chand, Meera
Dabrera, Gavin
Thelwall, Simon
author_sort Harman, Katie
collection PubMed
description There are concerns that sotrovimab has reduced efficacy at reducing hospitalisation risk against the BA.2 sub‐lineage of the Omicron SARS‐CoV‐2 variant. We performed a retrospective cohort (n = 8850) study of individuals treated with sotrovimab in the community, with the objective of assessing whether there were any differences in risk of hospitalisation of BA.2 cases compared with BA.1. We estimated that the hazard ratio of hospital admission with a length of stay of 2 days or more was 1.17 for BA.2 compared with BA.1 (95%CI 0.74–1.86). These results suggest that the risk of hospital admission was similar between the two sub‐lineages.
format Online
Article
Text
id pubmed-10225304
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-102253042023-05-30 Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England Harman, Katie Nash, Sophie Grace Webster, Harriet H. Groves, Natalie Hardstaff, Jo Bridgen, Jessica Blomquist, Paula B. Hope, Russell Ashano, Efejiro Myers, Richard Rokadiya, Sakib Hopkins, Susan Brown, Colin S. Chand, Meera Dabrera, Gavin Thelwall, Simon Influenza Other Respir Viruses Short Communications There are concerns that sotrovimab has reduced efficacy at reducing hospitalisation risk against the BA.2 sub‐lineage of the Omicron SARS‐CoV‐2 variant. We performed a retrospective cohort (n = 8850) study of individuals treated with sotrovimab in the community, with the objective of assessing whether there were any differences in risk of hospitalisation of BA.2 cases compared with BA.1. We estimated that the hazard ratio of hospital admission with a length of stay of 2 days or more was 1.17 for BA.2 compared with BA.1 (95%CI 0.74–1.86). These results suggest that the risk of hospital admission was similar between the two sub‐lineages. John Wiley and Sons Inc. 2023-05-28 /pmc/articles/PMC10225304/ /pubmed/37246147 http://dx.doi.org/10.1111/irv.13150 Text en © 2023 Crown copyright. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd. This article is published with the permission of the Controller of HMSO and the King’s Printer for Scotland. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communications
Harman, Katie
Nash, Sophie Grace
Webster, Harriet H.
Groves, Natalie
Hardstaff, Jo
Bridgen, Jessica
Blomquist, Paula B.
Hope, Russell
Ashano, Efejiro
Myers, Richard
Rokadiya, Sakib
Hopkins, Susan
Brown, Colin S.
Chand, Meera
Dabrera, Gavin
Thelwall, Simon
Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England
title Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England
title_full Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England
title_fullStr Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England
title_full_unstemmed Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England
title_short Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England
title_sort comparison of the risk of hospitalisation among ba.1 and ba.2 covid‐19 cases treated with sotrovimab in the community in england
topic Short Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225304/
https://www.ncbi.nlm.nih.gov/pubmed/37246147
http://dx.doi.org/10.1111/irv.13150
work_keys_str_mv AT harmankatie comparisonoftheriskofhospitalisationamongba1andba2covid19casestreatedwithsotrovimabinthecommunityinengland
AT nashsophiegrace comparisonoftheriskofhospitalisationamongba1andba2covid19casestreatedwithsotrovimabinthecommunityinengland
AT websterharrieth comparisonoftheriskofhospitalisationamongba1andba2covid19casestreatedwithsotrovimabinthecommunityinengland
AT grovesnatalie comparisonoftheriskofhospitalisationamongba1andba2covid19casestreatedwithsotrovimabinthecommunityinengland
AT hardstaffjo comparisonoftheriskofhospitalisationamongba1andba2covid19casestreatedwithsotrovimabinthecommunityinengland
AT bridgenjessica comparisonoftheriskofhospitalisationamongba1andba2covid19casestreatedwithsotrovimabinthecommunityinengland
AT blomquistpaulab comparisonoftheriskofhospitalisationamongba1andba2covid19casestreatedwithsotrovimabinthecommunityinengland
AT hoperussell comparisonoftheriskofhospitalisationamongba1andba2covid19casestreatedwithsotrovimabinthecommunityinengland
AT ashanoefejiro comparisonoftheriskofhospitalisationamongba1andba2covid19casestreatedwithsotrovimabinthecommunityinengland
AT myersrichard comparisonoftheriskofhospitalisationamongba1andba2covid19casestreatedwithsotrovimabinthecommunityinengland
AT rokadiyasakib comparisonoftheriskofhospitalisationamongba1andba2covid19casestreatedwithsotrovimabinthecommunityinengland
AT hopkinssusan comparisonoftheriskofhospitalisationamongba1andba2covid19casestreatedwithsotrovimabinthecommunityinengland
AT browncolins comparisonoftheriskofhospitalisationamongba1andba2covid19casestreatedwithsotrovimabinthecommunityinengland
AT chandmeera comparisonoftheriskofhospitalisationamongba1andba2covid19casestreatedwithsotrovimabinthecommunityinengland
AT dabreragavin comparisonoftheriskofhospitalisationamongba1andba2covid19casestreatedwithsotrovimabinthecommunityinengland
AT thelwallsimon comparisonoftheriskofhospitalisationamongba1andba2covid19casestreatedwithsotrovimabinthecommunityinengland

Ejemplares similares